MX2017015424A - Nanoparticulas para su uso como vacuna terapeutica. - Google Patents

Nanoparticulas para su uso como vacuna terapeutica.

Info

Publication number
MX2017015424A
MX2017015424A MX2017015424A MX2017015424A MX2017015424A MX 2017015424 A MX2017015424 A MX 2017015424A MX 2017015424 A MX2017015424 A MX 2017015424A MX 2017015424 A MX2017015424 A MX 2017015424A MX 2017015424 A MX2017015424 A MX 2017015424A
Authority
MX
Mexico
Prior art keywords
nanoparticles
therapeutic vaccine
cancer
radiotherapy
context
Prior art date
Application number
MX2017015424A
Other languages
English (en)
Spanish (es)
Inventor
Levy Laurent
Marill Julie
Pottier Agnés
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MX2017015424A publication Critical patent/MX2017015424A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017015424A 2015-05-28 2016-05-27 Nanoparticulas para su uso como vacuna terapeutica. MX2017015424A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305810 2015-05-28
PCT/EP2016/061989 WO2016189125A1 (en) 2015-05-28 2016-05-27 Nanoparticles for use as a therapeutic vaccine

Publications (1)

Publication Number Publication Date
MX2017015424A true MX2017015424A (es) 2018-03-01

Family

ID=53298299

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017015424A MX2017015424A (es) 2015-05-28 2016-05-27 Nanoparticulas para su uso como vacuna terapeutica.
MX2023007706A MX2023007706A (es) 2015-05-28 2017-11-28 Nanoparticulas para su uso como vacuna terapeutica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023007706A MX2023007706A (es) 2015-05-28 2017-11-28 Nanoparticulas para su uso como vacuna terapeutica.

Country Status (19)

Country Link
US (2) US11096962B2 (enExample)
EP (1) EP3302419A1 (enExample)
JP (2) JP2018516256A (enExample)
KR (1) KR102727195B1 (enExample)
CN (2) CN118286421A (enExample)
AR (1) AR104806A1 (enExample)
AU (2) AU2016269146B2 (enExample)
BR (1) BR112017025553A2 (enExample)
CA (1) CA2987331A1 (enExample)
EA (1) EA201792560A1 (enExample)
HK (1) HK1246160A1 (enExample)
IL (1) IL255853B (enExample)
MA (1) MA43100A (enExample)
MX (2) MX2017015424A (enExample)
NZ (1) NZ738527A (enExample)
TW (2) TWI873079B (enExample)
UA (1) UA124572C2 (enExample)
WO (1) WO2016189125A1 (enExample)
ZA (1) ZA201708686B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424533A1 (en) * 2017-07-05 2019-01-09 Nh Theraguix Methods for treating tumors
CN109010828B (zh) * 2018-10-12 2020-10-20 中国科学院高能物理研究所 一种二硫化钼/二氧化铪的复合纳米材料、其制备方法及用途
CA3115677A1 (en) 2018-10-19 2020-04-23 University Of Rochester Immune modulators in combination with radiation treatment for advanced pancreatic cancer
AU2021374754A1 (en) * 2020-11-05 2023-06-22 Nanobiotix Compositions of nanoparticles for treatment of cancer
CN120417926A (zh) 2022-12-12 2025-08-01 纳米生物技术公司 用作放射增敏剂或用于可视化生物组织的新型金属氧化物纳米颗粒及其组合物
CN116370625B (zh) * 2023-03-14 2024-10-11 浙江大学 一种哑铃状的金-氧化铈纳米材料的制备方法及其产品和应用

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
US4672040A (en) 1983-05-12 1987-06-09 Advanced Magnetics, Inc. Magnetic particles for use in separations
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US6099457A (en) 1990-08-13 2000-08-08 Endotech, Inc. Endocurietherapy
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
CA2137145A1 (en) 1992-06-08 1993-12-23 Mark S. Chagnon Preparation of controlled size inorganic particles for use in separations, as magnetic molecular switches, and as inorganic liposomes for medical applications
WO1994002068A1 (en) 1992-07-21 1994-02-03 The General Hospital Corporation System of drug delivery to the lymphatic tissues
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
JP2930421B2 (ja) 1994-02-28 1999-08-03 メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤組成物、その製造方法及びその使用方法
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
WO1998040049A2 (de) 1997-03-07 1998-09-17 Max-Delbrück-Centrum für Molekulare Medizin Spezifische magnetosomen, verfahren zu ihrer herstellung und ihre verwendung
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19726282A1 (de) 1997-06-20 1998-12-24 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern
US6161034A (en) 1999-02-02 2000-12-12 Senorx, Inc. Methods and chemical preparations for time-limited marking of biopsy sites
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6645464B1 (en) 1998-07-30 2003-11-11 James F. Hainfeld Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy
AU4305101A (en) 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
EP2343047B2 (en) 2000-02-08 2021-03-17 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
ES2258527T3 (es) 2000-05-05 2006-09-01 Bayer Technology Services Gmbh Nanoparticulas impurificadas como biomarcadores.
WO2002029410A2 (en) 2000-10-06 2002-04-11 Quantum Dot Corporation Cells having a spectral signature, and methods of preparation and use thereof
BR0115127A (pt) 2000-11-20 2004-02-17 Oncolytics Biotech Inc Método de fornecer um vìrus a um tumor sólido para reduzir crescimento do tumor
US20020127224A1 (en) 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
US6756063B2 (en) 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
DE10154016B4 (de) 2001-10-26 2004-02-12 Berlin Heart Ag Magnetflüssigkeit und Verfahren zur ihrer Herstellung
AU2002351240A1 (en) 2002-03-08 2003-09-22 James Hainfeld Gold nanoparticles used for x-rays imaging
US20030191458A1 (en) 2002-04-03 2003-10-09 Cornelius Diamond Light-activated drug delivery method and device
US7769423B2 (en) 2002-09-11 2010-08-03 Duke University MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
US20030125283A1 (en) 2002-09-16 2003-07-03 Gatenby Robert A. Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targetting agents
CA2513759C (en) 2003-01-24 2014-05-13 The Research Foundation Of State University Of New York Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same
US7235228B2 (en) 2003-04-15 2007-06-26 The United States Of America As Represented By The Secretary Of The Navy Fluorescent-magnetic nanoparticles with core-shell structure
US20050084869A1 (en) 2003-10-20 2005-04-21 Sung Hyun Kim Novel composition and methods for the diagnosis of lung cancer
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
JP2007511503A (ja) 2003-11-17 2007-05-10 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 医療画像化技術用の造影剤及びその使用
AU2004308756B2 (en) 2003-12-22 2010-06-24 Bracco Suisse S.A. Gas-filled microvesicle assembly for contrast imaging
US20080193372A1 (en) 2004-02-10 2008-08-14 Barnes-Jewish Hospital Efficacy and Safety of Targeted Particulate Agents with Decoy Systems
JP4895151B2 (ja) 2004-02-27 2012-03-14 日立金属株式会社 鉄系ナノサイズ粒子およびその製造方法
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
US20050260137A1 (en) 2004-05-18 2005-11-24 General Electric Company Contrast agents for magnetic resonance imaging
US20070031337A1 (en) 2004-06-22 2007-02-08 Reinhard Schulte Nanoparticle enhanced proton computed tomography and proton therapy
GB2415374A (en) 2004-06-25 2005-12-28 Leuven K U Res & Dev Targeted delivery of biologically active substances using iron oxide/gold core-shell nanoparticles
WO2006037081A2 (en) 2004-09-28 2006-04-06 The Regents Of The University Of California Nanoparticle radiosensitizers
FR2877571B1 (fr) 2004-11-05 2007-04-13 Nanobiotix Sarl Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations
JP5082446B2 (ja) 2004-11-10 2012-11-28 コニカミノルタエムジー株式会社 被覆磁性粒子含有製剤およびその製造方法、並びに診断治療システム
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
FR2884149B1 (fr) 2005-04-12 2007-06-08 Henri Mehier Tube implantable destine a l'injection notamment de fluide caloporteur dans tout ou partie d'un tissu humain ou animal
US20070092927A1 (en) 2005-06-13 2007-04-26 University Of Dayton Photocatalytic particles with directed and controlled redox activity
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
WO2007052267A2 (en) 2005-11-01 2007-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Biodegradable composite for internal local radiotherapy
US20070098641A1 (en) 2005-11-02 2007-05-03 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography
KR100745744B1 (ko) 2005-11-11 2007-08-02 삼성전기주식회사 나노 입자 코팅 방법
WO2007122956A1 (ja) 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
WO2007116954A2 (en) 2006-03-30 2007-10-18 Fujifilm Corporation Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
EP1852107A1 (en) 2006-04-19 2007-11-07 Nanobiotix Magnetic nanoparticles compositions and uses thereof
US20090181076A1 (en) 2006-05-04 2009-07-16 University Of South Australia Drug Release From Nanoparticle-Coated Capsules
RU2009104312A (ru) 2006-07-10 2010-08-20 Конинклейке Филипс Электроникс Н.В. (Nl) Наночастицы типа "ядро-оболочка" для терапии и диагностических целей
DE102006041495A1 (de) 2006-08-29 2008-03-20 Friedrich-Schiller-Universität Jena Substanzgemisch zur lokalen Deposition von Magnetpartikeln in einem Medium, insbesondere in tumorbefallenem organischem Gewebe, sowie Applikationskit zur Verabreichung
NO329127B1 (no) 2006-09-12 2010-08-30 Epitarget As Sporbart partikulaert materiale for legemiddelavlevering omfattende et matriseeller membranmateriale, et legemiddel, og et T1- og et T2*- magnetisk resonanskontrastmiddel
NO20064315L (no) 2006-09-22 2008-03-24 Epitarget As T1 MRI-sporbare medikamentavleveringspartikler and anvendelse derav
IL181126A0 (en) 2006-11-01 2007-07-04 S B Biotechnologies Ltd Preparation of gold-containing nano-liposome particles and their use in medical therapy
EP1920784A1 (en) 2006-11-13 2008-05-14 Koninklijke Philips Electronics N.V. Radiation sensitizers in ionizing radiation therapy and imaging
US20090004258A1 (en) 2007-06-27 2009-01-01 National Health Research Institutes Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field
EA201070296A1 (ru) 2007-08-21 2010-08-30 Алза Корпорейшн Липосомные композиции для введения in vivo соединений бороновой кислоты
JP2009067613A (ja) 2007-09-11 2009-04-02 Fujifilm Corp コア−シェル型金属酸化物微粒子及びその製造方法
US20120176016A1 (en) 2007-09-28 2012-07-12 General Electric Company Core-shell particulates, articles, and method of making
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
EP2067485A1 (en) 2007-12-07 2009-06-10 Koninklijke Philips Electronics N.V. Drug carrier providing MRI contrast enhancement
EP2231765A2 (en) 2007-12-21 2010-09-29 University Of Guelph Polysaccharide nanoparticles
DE102008003615A1 (de) 2008-01-09 2009-07-16 Magforce Nanotechnologies Ag Magnetische Transducer
DE102008008522A1 (de) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
WO2009105774A2 (en) 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
DE102008000852A1 (de) 2008-03-27 2009-10-01 Bosch Mahle Turbo Systems Gmbh & Co. Kg Abgasturbolader für ein Kraftfahrzeug
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US20130023714A1 (en) 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
US8395131B2 (en) 2009-06-20 2013-03-12 Xiaodong Wu Method for three dimensional (3D) lattice radiotherapy
EP2275137A1 (en) 2009-07-10 2011-01-19 Nanobiotix Metallic nanoparticles, preparation and uses thereof
EP2305310A1 (en) 2009-09-25 2011-04-06 Asociación Centro de Investigación Cooperativa en Biomateriales - CIC biomaGUNE Gold -coated magnetic glyconanoparticles functionalised with proteins for use as diagnostic and therapeutic agents
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
EP3960215B1 (en) 2009-12-15 2024-10-16 Incept, LLC Implants and biodegradable fiducial markers
CN102781472B (zh) 2010-02-17 2014-07-02 国立大学法人神户大学 放射线治疗剂
HRP20160609T1 (hr) 2010-03-26 2016-09-23 Abraxis Bioscience, Llc Postupci liječenja hepatocelularnog karcinoma
WO2011133228A2 (en) 2010-04-23 2011-10-27 Pixelligent Technologies, Llc Synthesis, capping and dispersion of nanocrystals
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
WO2012009406A2 (en) 2010-07-13 2012-01-19 University Of Utah Research Foundation Gold particles and methods of making and using the same in cancer treatment
EP2624874A4 (en) 2010-10-08 2014-04-02 Univ Texas Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
WO2012051220A1 (en) 2010-10-11 2012-04-19 Wichita State University Composite magnetic nanoparticle drug delivery system
US20140227343A1 (en) 2011-01-31 2014-08-14 Centre National De La Recherche Scientifique Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles
CN103429227B (zh) 2011-01-31 2017-12-19 纳米生物技术公司 纳米粒子递送系统、其制备及应用
JP2014516960A (ja) * 2011-05-19 2014-07-17 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ヒトｈｅｒ３抗体及びその使用
US10251841B2 (en) 2011-10-17 2019-04-09 Trustees Of Boston University Polymeric depots for localization of agent to biological sites
US10064960B2 (en) 2011-11-25 2018-09-04 Danmarks Tekniske Universitet Formulation of solid nano-sized particles in a gel-forming system
MX362089B (es) 2011-12-16 2019-01-07 Nanobiotix Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos.
IN2014MN02089A (enExample) 2012-03-20 2015-09-11 Einstein Coll Med
WO2014039874A2 (en) 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US20140213765A1 (en) 2013-01-25 2014-07-31 I-Liang Lee Albumin tissue scaffold
CA2897362C (en) 2013-01-25 2023-02-14 Nanobiotix Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer
US20140219926A1 (en) 2013-02-01 2014-08-07 The Trustees Of Dartmouth College Biodegradable Iron Oxide Nanoparticle Gel for Tumor Bed Therapy
BR112015029853A2 (pt) 2013-05-30 2017-07-25 Nanobiotix uso de uma composição farmacêutica
MA38709A1 (fr) 2013-06-20 2018-05-31 Nanobiotix Compositions et procédés pour une utilisation en diagnostic médical
AU2014283232B2 (en) 2013-06-20 2019-03-28 Nanobiotix Compositions and methods for use in oncology
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
CA2968473A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
JP6789960B2 (ja) 2014-11-25 2020-11-25 キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ 医薬組成物、その調製及び使用
PL3229843T3 (pl) 2014-11-25 2020-06-29 Curadigm Sas Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
LT3223796T (lt) 2014-11-25 2021-10-25 Curadigm Sas Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai

Also Published As

Publication number Publication date
AU2021202582A1 (en) 2021-05-27
NZ738527A (en) 2022-07-01
CN118286421A (zh) 2024-07-05
ZA201708686B (en) 2025-03-26
US20210353670A1 (en) 2021-11-18
CA2987331A1 (en) 2016-12-01
NZ776598A (en) 2024-10-25
UA124572C2 (uk) 2021-10-13
BR112017025553A2 (pt) 2018-08-07
US20180147237A1 (en) 2018-05-31
TW202417036A (zh) 2024-05-01
CN107708668A (zh) 2018-02-16
MA43100A (fr) 2018-09-05
AU2016269146B2 (en) 2021-01-28
EA201792560A1 (ru) 2018-06-29
US11096962B2 (en) 2021-08-24
TWI873079B (zh) 2025-02-21
JP2023082080A (ja) 2023-06-13
HK1246160A1 (zh) 2018-09-07
AR104806A1 (es) 2017-08-16
MX2023007706A (es) 2023-07-10
TW201705977A (zh) 2017-02-16
KR20180012823A (ko) 2018-02-06
EP3302419A1 (en) 2018-04-11
IL255853B (en) 2020-08-31
IL255853A (en) 2018-01-31
AU2021202582B2 (en) 2022-12-15
JP7570134B2 (ja) 2024-10-21
WO2016189125A1 (en) 2016-12-01
AU2016269146A1 (en) 2018-01-18
KR102727195B1 (ko) 2024-11-06
JP2018516256A (ja) 2018-06-21

Similar Documents

Publication Publication Date Title
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2022001105A (es) Anticuerpos anti tigit.
MY187540A (en) Compounds active towards bromodomains
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
ZA201708686B (en) Nanoparticles for use as a therapeutic vaccine
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
IL276733A (en) Use of Aribolin in cancer treatment
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
IL290251A (en) Combination for effective treatment of metastatic cancer in patients
PH12016501838A1 (en) Compounds and their methods of use
PL3258931T3 (pl) Zastosowanie kabazitakselu w leczeniu nowotworu złośliwego prostaty
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
PL3236967T3 (pl) Zapobieganie i leczenie przerzutów u pacjentów z nadpłytkowością typu nowotworowego
ZA201902951B (en) Nutritional composition for use in therapy of cancer patients
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
LV15384A (lv) 1-Acetil-5-nitro-4-fenil-3-pirolin-2-ons pielietošanai vēža ārstēšanā
GB201609690D0 (en) Therapeutic use of norfluxetine in breast cancer treatment
GB201612794D0 (en) Therapeutic use of diethanololeamide in prostate cancer treatment
GB2546703A (en) Compounds
GB201512260D0 (en) Improvements in or relating to beauty, health, or therapeutic treatments
HK1261631B (en) Combination for the effective treatment of metastatic cancer in patients
GB201416605D0 (en) Combination therapy to reduce the risk of and to treat cancer